Brent Meadows
Brent Meadows is Chief Business Officer of Lytix BioPharma AS, where he leads global business development and corporate strategy for their next-generation immuno-oncology therapeutics designed to activate durable anti-tumor immune responses. He assumed this role in March 2025.
An industry veteran with senior leadership experience at Johnson & Johnson, Bristol Myers Squibb, Regeneron, and multiple oncology-focused biotechnology companies, Brent has played a central role in the global launch and lifecycle strategy of novel oncology and immuno-oncology agents, spanning both solid tumors and hematologic malignancies. His experience includes building and leading launch marketing organizations, structuring complex in- and out-licensing transactions, and supporting assets from late-stage development through FDA and EMA approval and launch uptake.
Notably, Brent was involved in the in-licensing of Johnson & Johnson’s first externally sourced oncology therapeutic, which ultimately achieved regulatory approval in both the U.S. and Europe, as well as Baxalta’s strategic immuno-oncology collaboration with Symphogen, encompassing six antibody-based I/O targets.
Driven by a conviction that transformative immunotherapies reach patients fastest when scientific differentiation, clinical strategy, and value creation are tightly aligned, Brent now serves as a fractional Chief Business Officer to multiple cutting-edge oncology and immuno-oncology companies. In this capacity, he helps leadership teams translate complex tumor immunology into clear strategic narratives, define development and partnering strategies, and execute high-impact collaborations with leading pharmaceutical companies, academic centers, and investors—particularly within the Boston/Cambridge ecosystem and globally.
Brent resides in the Boston area with his wife, Elizabeth, and their Springer Spaniel, Sadie.
